There will be another satellite symposium during the May ERA-EDTA meeting. The previous ones done at ESC and ERA-EDTA meetings have been great and if you haven't watched them you should and they are accessible from the pace-cme.org page as well. Another opportunity to highlight apabetalone to researchers and clinicians. Hopefully the kidney trial will have started by then. Thanks to rndtbl on Investor Village and Jk on Stockhouse for posting. May and June offer multiple opportunities for presentations, though I don't know if Resverlogix will present at them. EAS, Vascular Discovery, ERA-EDTA, ADA, BIO International. 

https://pace-cme.org/2018/02/21/epigenetics-in-ckd-cvd-a-potential-breakthrough-therapy/